Takeda Oncology
Hanyang Liu is a research scientist specializing in in vivo pharmacology with a focus on cancer treatments, currently employed at Takeda Oncology since July 2022. Previous roles include serving as an associate scientist in immuno-oncology at Takeda and as a research associate at SQZ Biotechnologies, where efforts concentrated on murine autoimmune disease models to evaluate cell therapies. Hanyang also has experience as a biological engineer at Bio-Tree Systems Inc., conducting preclinical drug efficacy studies, and as a graduate student at Brown University, with a research emphasis on antimicrobial coating development. Hanyang holds a Master of Science in Biomedical/Medical Engineering from Brown University and a Bachelor of Science in the same field from the University of Rochester. Additionally, Hanyang participated in a program at Harvard Medical School in 2022.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.